GET 2024 will cover medical advances and contemporary clinical topics†.
|
Saturday 17th August |
||||
|
10:00am |
10:50am |
Arrival Morning Tea |
||
|
10:50am |
11:00am |
Welcome and opening of GET |
Dr Daniela van Vuuren
|
|
|
SESSION 1 – CAR-T Chair: Dr Jason Butler |
||||
|
11:00am |
11:30am |
Lymphoma |
||
|
11:30am |
11:50am |
CAR-T RWE |
||
|
11:50am |
12:10pm
|
ALL |
||
|
12:10pm |
12:40pm |
Myeloma |
||
|
12:40pm |
1:00pm |
Panel Discussion & Q&A |
||
|
1:00pm |
1:45pm |
Lunch Break |
||
|
SESSION 2 – MPNs Chair: Dr Cecily Forsyth |
||||
|
1:45pm |
2:15pm |
Management of Polycythaemia Vera: A Community Haematologist’s Experience |
||
|
2:15pm |
2:45pm |
New Approaches to Managing MF |
||
|
2:45pm |
3:15pm |
State of the Art Diagnostics – Molecular Prognostication and Management of MPNs
|
||
|
3:15pm
|
3:40pm |
Panel Discussion & Q&A
|
||
|
3:40pm |
4:00pm |
Afternoon Tea |
||
|
SESSION 3 – CLASSICAL HAEMATOLOGY Chair: Dr Danny Hsu |
||||
|
4:00pm |
4:30pm |
ITP |
||
|
4:30pm |
5:00pm |
PNH
|
||
|
5:00pm |
5:15pm |
Case Study |
||
|
5:15pm |
5:30pm |
Panel Discussion & Q&A
|
||
|
5:30pm |
Close Day 1 & Networking Pre-Dinner Drinks |
|||
|
6:30pm |
8:15pm |
Networking Dinner |
||
|
Sunday 18th August |
|||
|
8:30am |
9:00am |
Arrival Morning Tea |
|
|
SESSION 4 – CML Chair: Prof Jake Shortt |
|||
|
09:00am |
09:20am |
Predicting Relapse in CML TFR |
|
|
09:20am |
10:00am |
CML Treatment Landscape |
|
|
10:00am |
10:15am |
Q&A |
|
|
10:15am |
10:45am |
Morning Tea |
|
|
SESSION 4 – CML (continued) Chair: Prof Jake Shortt |
|||
|
10:45am |
11:30am |
CML Highlights from 2024 ASCO & EHA
|
|
|
11:30am |
11:40am |
Q&A |
|
|
11:40am |
12:30pm |
CML Clinical Panel Discussion |
|
|
12:30pm |
1:30pm |
Lunch |
|
|
SESSION 5 – AML Chair: Dr Chun Fong |
|||
|
1:30pm |
1:50pm |
Recent Advancements and Challenges in AML including Novel Therapies
|
|
|
1:50pm |
2:10pm |
Harnessing Artificial Intelligence (AI) for Genetic Risk Profiling in AML
|
|
|
2:10pm |
2:30pm |
The Role of Measurable Residual Disease (MRD) as a Predictive Biomarker to Guide Therapy in AML |
|
|
2:30pm |
3:00pm |
Panel Discussion & Q&A |
|
|
3:00pm |
Close Day 2 |
||
|
Saturday 17th August |
|||
|
09:00am |
10:50am |
Meet and Greet (Light Breakfast and morning tea on arrival) |
Early check in – pick up badges |
|
10:50am |
10:55am |
Welcome and opening of GET |
Dr Daniela Vanvuuren / Matt Zellor
|
|
10:55am |
11:00am |
Introduction |
Chair: Dr Jason Butler (Chair) |
|
1:35pm |
2:45pm |
Session 1 – GVHD |
Chair: Nada Hamad |
|
GVHD – Acute/chronic GVHD |
|||
|
GVHD – Dosing & drug-drug interaction |
|||
|
GVHD – Nurse Consultant Perspective |
|||
|
Panel Discussion |
|||
|
2:45pm |
3:15pm |
Afternoon Tea |
|
|
3:15pm |
4:15pm |
Session 2 – Approaches to treating ITP and PNH in an era of expanding choices |
Chair: Jeff Szer |
|
PNH |
|||
|
ITP |
|||
|
Q&A / Panel discussion |
|||
|
4:15pm |
5:40pm |
Session 3 – MPN |
Chair: Andrew Perkins |
|
Use of NGS in diagnosis of MPNs |
|||
|
SH2B3 in MPNs |
|||
|
Novel combinations in MF |
|||
|
Q&A / Panel Discussion |
|||
|
5:40pm |
6:40pm |
Networking – Drinks & Canapes |
|
|
6:45pm |
8:50pm |
Dinner |
|
|
Transplant in Haematology |
|||
|
Saturday 29th July |
|||
|
8:00am |
8:25am |
Registration & Arrival Tea and Coffee |
|
|
8:25am |
8:30am |
Welcome |
Novartis |
|
8:30am |
10:00am |
Session 4 – CML |
Chair: David Yeung, Tim Hughes |
|
Recent Advances in CML Managements – Updates from EHA 2023 / ASH2022 |
|||
|
How to improve eligibility (Early milestone of response) and success of TFR / Second TFR |
|||
|
10:00am |
10:20am |
Morning Tea |
|
|
10:20am |
12:05pm |
ASCEMBL Data Overview / ASCEND / MAP Australia Data |
|
|
Real World Experience with Frontline therapies against CML |
|||
|
Q&A / Panel Discussion |
|||
|
12:05pm |
12:50pm |
Lunch |
|
|
12:50pm |
2:50pm |
Session 5 – AML & MDS |
Chair: Andrew Wei
|
|
Clonal haematopoiesis – what a haematologist needs to know |
|||
|
Key Questions in MDS |
|||
|
Key Questions in AML |
|||
|
Panel Discussion |
|||
|
2:50pm |
3:00pm |
Close |
|
|
3:00pm |
Departures |
||
†Agenda is subject to change.